Program
vorolanib
Also written as “EYP-1901”, “CM082” and “CM082 plus JS001”.
Its studies are mostly in Macular Degeneration · Macular Edema · Carcinoma, Renal Cell · Diabetic Retinopathy · Neoplasms, led by 3 companies.
Drug pageVorolanib: every studyAll 35 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Betta Pharmaceuticalsits history only | 141 open or running | phase 3since Mar 23, 2017 | May 22, 2013 | Jun 2027phase 1 · NCT07809802 |
| EyePoint Pharmaceuticalsits history only | 84 open or running | phase 3since Oct 30, 2024 | Feb 6, 2021 | Oct 2027phase 3 · NCT07449923 |
| Tyrogenex | 20 open or running | phase 2since Jan 21, 2015 | Feb 14, 2011 | none ahead |
Also a collaborator on its studies: SynteractHCR.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Tyrogenex only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Feb 14, 2011First study: phase 1 study in NeoplasmsFirst studyNCT01296581 · 52 enrolled · United States
- Jan 21, 2015Phase 2 study in Macular DegenerationNCT02348359 · 157 enrolled · United States
- Jun 9, 2016Named vorolanibINNProposed as its International Nonproprietary Name in WHO's List 115 · before, EYP-1901, CM082
TargetBeta
“Vorolanib, a next-generation vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitor (TKI), exhibits unique pharmacodynamic properties that warrant investigation in adjuvant paradigms.”study text, by rule · the study
Other programs on KDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Ramucirumabrule | Eli Lilly | phase 3 | 58 |
| apatinibrule | Jiangsu HengRui Medicine | phase 3 | 47 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
| Aurora B/VEGFR/FGFR Inhibitor AL8326rule | advenchen-laboratories-nanjing-ltd | phase 3 | 8 |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | beijing-konruns-pharmaceutical-co-ltd | phase 3 | 7 |
Studies
All 2 Tyrogenex leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02348359Macular Degeneration · United States | 2 | Terminated | Dec 12, 2017 | 157 |
| NCT01296581Neoplasms · United States | 1 | Completed | Jan 2014 | 52 |
How it is read
Names in the registry
- “EYP-1901”, 8 entries
- “CM082”, 5 entries
- “CM082 plus JS001”, 3 entries
- “vorolanib”, 2 entries
- “X-82”, 2 entries
Conditions, from the studies’ own filings
- Macular Degeneration, 7 studies
- Macular Edema, 3 studies
- Carcinoma, Renal Cell, 2 studies
- Diabetic Retinopathy, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.